Pipeline Watch: Phase III Read-Outs For Zanubrutinib, Surufatinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.  

Pipeline Watch regular column feature image

More from Pipeline Watch

More from R&D